Have a feature idea you'd love to see implemented?
Let us know!
RYTM Rhythm Pharmaceuticals Inc
Price (delayed)
$49.71
Market cap
$3.04B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.36
Enterprise value
$2.88B
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within
Highlights
The gross profit has soared by 134% YoY and by 11% from the previous quarter
RYTM's revenue has soared by 133% YoY and by 11% QoQ
RYTM's net income is down by 42% year-on-year but it is up by 5% since the previous quarter
The EPS has contracted by 33% YoY but it has grown by 6% from the previous quarter
The debt has surged by 155% year-on-year
Rhythm Pharmaceuticals's equity has plunged by 78% YoY and by 36% from the previous quarter
Key stats
What are the main financial stats of RYTM
Market
Valuations
Earnings
Shares outstanding
61.13M
Market cap
$3.04B
Enterprise value
$2.88B
Price to earnings (P/E)
N/A
Price to book (P/B)
77.04
Price to sales (P/S)
29.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.3
Revenue
$101.78M
EBIT
-$241.03M
EBITDA
-$239.38M
Free cash flow
-$128.45M
Per share
Balance sheet
Liquidity
EPS
-$4.36
Free cash flow per share
-$2.11
Book value per share
$0.65
Revenue per share
$1.67
TBVPS
$6.15
Total assets
$381.85M
Total liabilities
$202.35M
Debt
$4.12M
Equity
$39.34M
Working capital
$302.64M
Debt to equity
0.1
Current ratio
6.53
Quick ratio
6.16
Net debt/EBITDA
0.66
Margins
Efficiency
Dividend
EBITDA margin
-235.2%
Gross margin
88.8%
Net margin
-254.9%
Operating margin
-260.9%
Return on assets
-78.6%
Return on equity
-222.8%
Return on invested capital
-128.2%
Return on capital employed
-73.7%
Return on sales
-236.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RYTM stock price
How has the Rhythm Pharmaceuticals stock price performed over time
Intraday
1.41%
1 week
-2.59%
1 month
-2.99%
1 year
121.92%
YTD
8.14%
QTD
-5.12%
Financial performance
How have Rhythm Pharmaceuticals's revenue and profit performed over time
Revenue
$101.78M
Gross profit
$90.38M
Operating income
-$265.58M
Net income
-$259.43M
Gross margin
88.8%
Net margin
-254.9%
The gross profit has soared by 134% YoY and by 11% from the previous quarter
RYTM's revenue has soared by 133% YoY and by 11% QoQ
Rhythm Pharmaceuticals's operating income has decreased by 47% YoY but it has increased by 2.3% QoQ
RYTM's net income is down by 42% year-on-year but it is up by 5% since the previous quarter
Growth
What is Rhythm Pharmaceuticals's growth rate over time
Valuation
What is Rhythm Pharmaceuticals stock price valuation
P/E
N/A
P/B
77.04
P/S
29.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.3
The EPS has contracted by 33% YoY but it has grown by 6% from the previous quarter
RYTM's P/B is 140% above its last 4 quarters average of 32.1
Rhythm Pharmaceuticals's equity has plunged by 78% YoY and by 36% from the previous quarter
RYTM's revenue has soared by 133% YoY and by 11% QoQ
RYTM's price to sales (P/S) is 10% higher than its last 4 quarters average of 27.2
Efficiency
How efficient is Rhythm Pharmaceuticals business performance
The ROE has plunged by 190% YoY and by 24% from the previous quarter
The ROA has plunged by 54% YoY but it has grown by 10% from the previous quarter
The ROS has grown by 39% YoY and by 15% from the previous quarter
Rhythm Pharmaceuticals's return on invested capital has decreased by 31% YoY but it has increased by 9% QoQ
Dividends
What is RYTM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RYTM.
Financial health
How did Rhythm Pharmaceuticals financials performed over time
The total assets is 89% more than the total liabilities
The total liabilities has soared by 59% YoY and by 2.7% from the previous quarter
The quick ratio has surged by 54% since the previous quarter and by 6% year-on-year
The debt is 90% smaller than the equity
The debt has surged by 155% year-on-year
Rhythm Pharmaceuticals's equity has plunged by 78% YoY and by 36% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.